WHO Expert Committee on Drug Dependence [meeting held in Geneva from 17 to 22 April 1989] : twenty-sixth report.
Material type: TextSeries: World Health Organization technical report series ; no. 787Publication details: Geneva : World Health Organization, 1989. Description: 32 pISBN: 9241207876Title translated: Comité OMS d' experts de la pharmacodépendance [réuni à Genève du 17 au 22 avril 1989] : vingt-sixième rapport; Comité de Expertos de la OMS en Farmacodependencia [se reunió en Ginebra del 17 al 22 abril de 1989] : 26o informeSubject(s): Substance-related disorders | Substance abuse | Drug and narcotic control | Benzodiazepines | Designer drugs | Tetrahydrocannabinol | Alcoholism and Drug AbuseNLM classification: WM 270Online resources: Click here to access online | Click here to access online Abstract: Records the recommendations of a WHO expert committee responsible for reviewing information on psychoactive drugs to assess the need for their international control under the Single Convention on Narcotic Drugs, 1961, or the Convention on Psychotropic Substances, 1971. Evaluations are presented for fourteen substances, including four benzodiazepines, nine designer drugs (analogues of fentanyl, tenamfetamine and aminorex), and dronabinol. Recommendations are based on a review of pharmacological and epidemiological data together with evidence indicating the potential of serious abuse-related social and health problems. For each drug, a summary of effects on the central nervous system, dependence potential, likelihood of abuse, and therapeutic usefulness is followed by the committee's recommendations on scheduling under the international treaties. Proposals include the recommended scheduling of the benzodiazepine midazolam and the rescheduling, to provide for less stringent control, of dronabinol, which may be useful as an antiemetic adjunct to cancer chemotherapy. The committee also recommended that all nine designer drugs be subject to international control. The report concludes with general recommendations concerning specifications for the types of information required to facilitate decision-making on the international control of psychoactive substances.Item type | Current library | Call number | Copy number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
DOCUMENT | WHO HQ READING-RM | HQ SERIAL (Browse shelf(Opens below)) | 1 | Available | 00021787 | |
DOCUMENT | WHO HQ READING-RM | HQ SERIAL RUS (Browse shelf(Opens below)) | 1 | Available | 00035353 | |
Books | WHO HQ ONLINE-IRIS | HQ SERIAL RUS (Browse shelf(Opens below)) | 2 | Available | O9241207876RUS | |
DOCUMENT | WHO HQ BORROWABLE-COLL-STACKS | WM 270 89WH-2 (Browse shelf(Opens below)) | 2 | Withdrawn | 00021788 | |
DOCUMENT | WHO HQ ONLINE-IRIS | WM 270 89WH-2 (Browse shelf(Opens below)) | 3 | Available | O9241207876 |
Records the recommendations of a WHO expert committee responsible for reviewing information on psychoactive drugs to assess the need for their international control under the Single Convention on Narcotic Drugs, 1961, or the Convention on Psychotropic Substances, 1971. Evaluations are presented for fourteen substances, including four benzodiazepines, nine designer drugs (analogues of fentanyl, tenamfetamine and aminorex), and dronabinol. Recommendations are based on a review of pharmacological and epidemiological data together with evidence indicating the potential of serious abuse-related social and health problems. For each drug, a summary of effects on the central nervous system, dependence potential, likelihood of abuse, and therapeutic usefulness is followed by the committee's recommendations on scheduling under the international treaties. Proposals include the recommended scheduling of the benzodiazepine midazolam and the rescheduling, to provide for less stringent control, of dronabinol, which may be useful as an antiemetic adjunct to cancer chemotherapy. The committee also recommended that all nine designer drugs be subject to international control. The report concludes with general recommendations concerning specifications for the types of information required to facilitate decision-making on the international control of psychoactive substances.
eng fre rus spa.
WHODOC
WHO monograph
4
There are no comments on this title.